1
|
Wang J, Zhang J, Yu ZL, Chung SK, Xu B. The roles of dietary polyphenols at crosstalk between type 2 diabetes and Alzheimer's disease in ameliorating oxidative stress and mitochondrial dysfunction via PI3K/Akt signaling pathways. Ageing Res Rev 2024; 99:102416. [PMID: 39002644 DOI: 10.1016/j.arr.2024.102416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2024] [Revised: 07/06/2024] [Accepted: 07/06/2024] [Indexed: 07/15/2024]
Abstract
Alzheimer's disease (AD) is a fatal neurodegenerative disease in which senile plaques and neurofibrillary tangles are crucially involved in its physiological and pathophysiological processes. Growing animal and clinical studies have suggested that AD is also comorbid with some metabolic diseases, including type 2 diabetes mellitus (T2DM), and therefore, it is often considered brain diabetes. AD and T2DM share multiple molecular and biochemical mechanisms, including impaired insulin signaling, oxidative stress, gut microbiota dysbiosis, and mitochondrial dysfunction. In this review article, we mainly introduce oxidative stress and mitochondrial dysfunction and explain their role and the underlying molecular mechanism in T2DM and AD pathogenesis; then, according to the current literature, we comprehensively evaluate the possibility of regulating oxidative homeostasis and mitochondrial function as therapeutics against AD. Furthermore, considering dietary polyphenols' antioxidative and antidiabetic properties, the strategies for applying them as potential therapeutical interventions in patients with AD symptoms are assessed.
Collapse
Affiliation(s)
- Jingwen Wang
- Food Science and Technology Program, Department of Life Sciences, BNU-HKBU United International College, Zhuhai, Guangdong 519087, China; Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China
| | - Jingyang Zhang
- Food Science and Technology Program, Department of Life Sciences, BNU-HKBU United International College, Zhuhai, Guangdong 519087, China
| | - Zhi-Ling Yu
- Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China
| | - Sookja Kim Chung
- Faculty of Medicine, Macau University of Science and Technology, Macau, China
| | - Baojun Xu
- Food Science and Technology Program, Department of Life Sciences, BNU-HKBU United International College, Zhuhai, Guangdong 519087, China.
| |
Collapse
|
2
|
Xu S, Chen Y, Gong Y. Improvement of Theaflavins on Glucose and Lipid Metabolism in Diabetes Mellitus. Foods 2024; 13:1763. [PMID: 38890991 PMCID: PMC11171799 DOI: 10.3390/foods13111763] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2024] [Revised: 05/28/2024] [Accepted: 06/03/2024] [Indexed: 06/20/2024] Open
Abstract
In diabetes mellitus, disordered glucose and lipid metabolisms precipitate diverse complications, including nonalcoholic fatty liver disease, contributing to a rising global mortality rate. Theaflavins (TFs) can improve disorders of glycolipid metabolism in diabetic patients and reduce various types of damage, including glucotoxicity, lipotoxicity, and other associated secondary adverse effects. TFs exert effects to lower blood glucose and lipids levels, partly by regulating digestive enzyme activities, activation of OATP-MCT pathway and increasing secretion of incretins such as GIP. By the Ca2+-CaMKK ꞵ-AMPK and PI3K-AKT pathway, TFs promote glucose utilization and inhibit endogenous glucose production. Along with the regulation of energy metabolism by AMPK-SIRT1 pathway, TFs enhance fatty acids oxidation and reduce de novo lipogenesis. As such, the administration of TFs holds significant promise for both the prevention and amelioration of diabetes mellitus.
Collapse
Affiliation(s)
- Shiyu Xu
- National Research Center of Engineering and Technology for Utilization of Botanical Functional Ingredients, Changsha 410128, China;
- Key Laboratory of Tea Science of Ministry of Education, Changsha 410128, China
| | - Ying Chen
- National Research Center of Engineering and Technology for Utilization of Botanical Functional Ingredients, Changsha 410128, China;
- Key Laboratory of Tea Science of Ministry of Education, Changsha 410128, China
| | - Yushun Gong
- Co-Innovation Center of Education Ministry for Utilization of Botanical Functional Ingredients, Changsha 410128, China
- Key Laboratory for Evaluation and Utilization of Gene Resources of Horticultural Crops, Ministry of Agriculture and Rural Affairs of China, Hunan Agricultural University, Changsha 410128, China
| |
Collapse
|
3
|
Bongu C, Khan AS, Arsalan M, Alsharaeh EH. Blackberry Seeds-Derived Carbon as Stable Anodes for Lithium-Ion Batteries. ACS OMEGA 2024; 9:16725-16733. [PMID: 38617659 PMCID: PMC11007718 DOI: 10.1021/acsomega.4c00797] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/24/2024] [Revised: 03/13/2024] [Accepted: 03/19/2024] [Indexed: 04/16/2024]
Abstract
The suitability of biocarbons derived from blackberry seeds as anode materials in lithium-ion batteries has been assessed for the first time. Blackberry seeds have antibacterial, anticancer, antidysentery, antidiabetic, antidiarrheal, and potent antioxidant properties and are generally used for herbal medical purposes. Carbon is extracted from blackberries using a straightforward carbonization technique and activated with KOH at temperatures 700, 800, and 900 °C. The physical characterization demonstrates that activated blackberry seeds-derived carbon at 900 °C (ABBSC-900 °C) have well-ordered graphene sheets with high defects compared to the ABBSC-700 °C and ABBSC-800 °C. It is discovered that an ABBSC-900 °C is mesoporous, with a notable Brunauer-Emmett-Teller surface area of 65 m2 g-1. ABBSC-900 has good electrochemical characteristics, as studied under 100 and 1000 mA g-1 discharge conditions when used as a lithium intercalating anode. Delivered against a 500 mA g-1 current density, a steady reversible capacity of 482 mA h g-1 has been achieved even after 200 cycles. It is thought that disordered mesoporous carbon with a large surface area account for the improved electrochemical characteristics of the ABBSC-900 anode compared to the other ABBSC-700 and ABBSC-800 carbons. The research shows how to use a waste product, ABBSC, as the most desired anode for energy storage applications.
Collapse
Affiliation(s)
- Chandra
Sekhar Bongu
- College
of Science and General Studies, AlFaisal
University, P.O. Box 50927, Riyadh 11533, Saudi Arabia
| | - Abeer Shiraz Khan
- College
of Science and General Studies, AlFaisal
University, P.O. Box 50927, Riyadh 11533, Saudi Arabia
| | - Muhammad Arsalan
- EXPEC
Advanced Research Center, Saudi Aramco, P.O. Box 5000, Dhahran 31311, Saudi Arabia
| | - Edreese H. Alsharaeh
- College
of Science and General Studies, AlFaisal
University, P.O. Box 50927, Riyadh 11533, Saudi Arabia
| |
Collapse
|
4
|
Zhang L, Muscat JE, Kris-Etherton PM, Chinchilli VM, Al-Shaar L, Richie JP. The Epidemiology of Berry Consumption and Association of Berry Consumption with Diet Quality and Cardiometabolic Risk Factors in United States Adults: The National Health and Nutrition Examination Survey, 2003-2018. J Nutr 2024; 154:1014-1026. [PMID: 38242289 DOI: 10.1016/j.tjnut.2024.01.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2023] [Revised: 01/10/2024] [Accepted: 01/16/2024] [Indexed: 01/21/2024] Open
Abstract
BACKGROUND Berries are rich in important nutrients and bioactive compounds, which could potentially contribute to maintenance of normal lipid and glucose profiles. OBJECTIVE We reported the epidemiology of berry consumption and examined associations of berry consumption with diet quality [measured by Healthy Eating Index (HEI-2015)] and levels of cardiometabolic risk factors, including body mass index (BMI), waist circumference (WC), systolic blood pressure (SBP), diastolic blood pressure, total cholesterol, high-density lipoprotein cholesterol (HDL cholesterol), glycated hemoglobin, and fasting biomarkers: triglycerides, low-density lipoprotein cholesterol (LDL cholesterol), glucose, insulin, and homeostasis model assessment of insulin resistance (HOMA-IR). METHODS We evaluated 33,082 adults (aged ≥20 y) using two 24-h diet recalls from National Health and Nutrition Examination Survey (2003-2018). Multivariable linear regression models were applied to examine the associations of total and individual berry intake with diet quality and cardiometabolic risk factors using appropriate sample weights. RESULTS Approximately 25 % of the United States adults consumed berries (0.08 ± 0.003 cup-equivalents/d), representing ∼10 % of the daily mean total fruit intake. Among berry consumers, the mean intake of strawberries (0.31 ± 0.01 cup-equivalents) was higher than for other berries. Berry consumers had a significantly higher HEI-2015 score than nonconsumers (mean HEI-2015 score = 58.8 compared with 52.3, P < 0.0001). Berry consumers had significantly lower concentrations of cardiometabolic indices than nonconsumers, including BMI, WC, SBP, total cholesterol, LDL cholesterol, triglycerides, fasting insulin, HOMA-IR, and higher mean HDL cholesterol, after adjusting for sociodemographic, lifestyle, and dietary confounders (all P < 0.05). CONCLUSIONS United States adult berry consumers had a higher diet quality and lower concentrations of cardiometabolic risk factors, suggesting a favorable role for berries in diets and cardiometabolic disease prevention in United States adult population.
Collapse
Affiliation(s)
- Li Zhang
- Department of Public Health Sciences, Penn State College of Medicine, Penn State Cancer Institute, Pennsylvania State University, Hershey, PA, United States.
| | - Joshua E Muscat
- Department of Public Health Sciences, Penn State College of Medicine, Penn State Cancer Institute, Pennsylvania State University, Hershey, PA, United States.
| | - Penny M Kris-Etherton
- Department of Nutritional Sciences, Pennsylvania State University, University Park, PA, United States
| | - Vernon M Chinchilli
- Department of Public Health Sciences, Penn State College of Medicine, Penn State Cancer Institute, Pennsylvania State University, Hershey, PA, United States
| | - Laila Al-Shaar
- Department of Public Health Sciences, Penn State College of Medicine, Penn State Cancer Institute, Pennsylvania State University, Hershey, PA, United States
| | - John P Richie
- Department of Public Health Sciences, Penn State College of Medicine, Penn State Cancer Institute, Pennsylvania State University, Hershey, PA, United States
| |
Collapse
|
5
|
Mattila M, Takkinen HM, Peltonen EJ, Vuorinen AL, Niinistö S, Metsälä J, Ahonen S, Åkerlund M, Hakola L, Toppari J, Ilonen J, Veijola R, Haahtela T, Knip M, Virtanen SM. Fruit, berry, and vegetable consumption and the risk of islet autoimmunity and type 1 diabetes in children-the Type 1 Diabetes Prediction and Prevention birth cohort study. Am J Clin Nutr 2024; 119:537-545. [PMID: 38142920 PMCID: PMC10884602 DOI: 10.1016/j.ajcnut.2023.12.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2023] [Revised: 11/30/2023] [Accepted: 12/19/2023] [Indexed: 12/26/2023] Open
Abstract
BACKGROUND Prospective studies investigating the association among fruit, berry, and vegetable consumption and the risk of islet autoimmunity (IA) and type 1 diabetes (T1D) are few. OBJECTIVES In this cohort study, we explored whether the consumption of fruits, berries, and vegetables is associated with the IA and T1D development in genetically susceptible children. METHODS Food consumption data in the Finnish Type 1 Diabetes Prediction and Prevention (DIPP) cohort study were available from 5674 children born between September 1996 and September 2004 in the Oulu and Tampere University Hospitals. Diet was assessed with 3-d food records at the age of 3 and 6 mo and annually from 1 to 6 y. The association between food consumption and the risk of IA and T1D was analyzed using joint models adjusted for energy intake, sex, human leukocyte antigen (HLA) genotype, and a family history of diabetes. RESULTS During the 6-y follow-up, 247 children (4.4%) developed IA and 94 (1.7%) T1D. Furthermore, 64 of 505 children with at least 1 repeatedly positive autoantibody (12.7%) progressed from islet autoantibody positivity to T1D. The consumption of cruciferous vegetables was associated with decreased risk of IA [hazard ratio (HR): 0.83; 95% credible intervals (CI): 0.72, 0.95, per 1 g/MJ increase in consumption] and the consumption of berries with decreased risk of T1D (0.60; 0.47, 0.89). The consumption of banana was associated with increased risk of IA (1.08; 1.04, 1.12) and T1D (1.11; 1.01, 1.21). Only the association between banana and IA remain significant after multiple testing correction. CONCLUSIONS In children genetically at risk for T1D, the consumption of cruciferous vegetables was associated with decreased risk of IA and consumption of berries with decreased risk of T1D. In addition, the consumption of banana was associated with increased risk of IA and T1D.
Collapse
Affiliation(s)
- Markus Mattila
- Faculty of Social Sciences, Unit of Health Sciences, Tampere University, Tampere, Finland; Tampere University Hospital, Wellbeing Services County of Pirkanmaa, Tampere, Finland; Department of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland.
| | - Hanna-Mari Takkinen
- Faculty of Social Sciences, Unit of Health Sciences, Tampere University, Tampere, Finland; Tampere University Hospital, Wellbeing Services County of Pirkanmaa, Tampere, Finland; Department of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland
| | - Essi J Peltonen
- Faculty of Social Sciences, Unit of Health Sciences, Tampere University, Tampere, Finland; Tampere University Hospital, Wellbeing Services County of Pirkanmaa, Tampere, Finland
| | - Anna-Leena Vuorinen
- Faculty of Social Sciences, Unit of Health Sciences, Tampere University, Tampere, Finland; Tampere University Hospital, Wellbeing Services County of Pirkanmaa, Tampere, Finland; Department of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland; Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
| | - Sari Niinistö
- Faculty of Social Sciences, Unit of Health Sciences, Tampere University, Tampere, Finland; Tampere University Hospital, Wellbeing Services County of Pirkanmaa, Tampere, Finland; Department of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland
| | - Johanna Metsälä
- Department of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland
| | - Suvi Ahonen
- Faculty of Social Sciences, Unit of Health Sciences, Tampere University, Tampere, Finland; Tampere University Hospital, Wellbeing Services County of Pirkanmaa, Tampere, Finland; Department of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland
| | - Mari Åkerlund
- Faculty of Social Sciences, Unit of Health Sciences, Tampere University, Tampere, Finland; Tampere University Hospital, Wellbeing Services County of Pirkanmaa, Tampere, Finland; Department of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland
| | - Leena Hakola
- Faculty of Social Sciences, Unit of Health Sciences, Tampere University, Tampere, Finland; Tampere University Hospital, Wellbeing Services County of Pirkanmaa, Tampere, Finland
| | - Jorma Toppari
- Institute of Biomedicine, Research Centre for Integrative Physiology and Pharmacology, and Centre for Population Health Research, University of Turku, Turku, Finland; Turku University Hospital, Department of Pediatrics, Turku, Finland
| | - Jorma Ilonen
- Immunogenetics Laboratory, Institute of Biomedicine, University of Turku, Turku, Finland
| | - Riitta Veijola
- Department of Pediatrics, PEDEGO Research Unit, Medical Research Center, University of Oulu, Oulu, Finland; Oulu University Hospital, Department of Children and Adolescents, Oulu, Finland
| | - Tari Haahtela
- Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland
| | - Mikael Knip
- Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Tampere University Hospital, Department of Pediatrics, Tampere, Finland
| | - Suvi M Virtanen
- Faculty of Social Sciences, Unit of Health Sciences, Tampere University, Tampere, Finland; Tampere University Hospital, Wellbeing Services County of Pirkanmaa, Tampere, Finland; Department of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland; Center for Child Health Research, Tampere University and Tampere University Hospital, Tampere, Finland
| |
Collapse
|
6
|
Zhang L, Muscat JE, Chinchilli VM, Kris-Etherton PM, Al-Shaar L, Richie JP. Consumption of Berries and Flavonoids in Relation to Mortality in NHANES, 1999-2014. J Nutr 2024; 154:734-743. [PMID: 38184200 DOI: 10.1016/j.tjnut.2024.01.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2023] [Revised: 12/28/2023] [Accepted: 01/03/2024] [Indexed: 01/08/2024] Open
Abstract
BACKGROUND Berries are foods that are abundant in nutrients, especially flavonoids, that promote good health; however, the effects of total berries on mortality are not well characterized. OBJECTIVES We evaluated whether intakes of total berries and specific berry types including blueberries, strawberries, cranberries, flavonoids, and subclasses of flavonoids (anthocyanidins, flavonols, flavones, flavanones, flavan-3-ols, and isoflavones) in relation to mortality risk in United States adults. METHODS A nationally representative sample of the United States adult population was obtained using data from the 1994-2014 NHANES (n = 37,232). Intake of berries was estimated using 24-h food recalls (1999-2014), and flavonoids intake was calculated using the matched USDA's expanded flavonoid database. Mortality outcomes based on 8 y of follow-up were obtained using linked death certificates. RESULTS Compared with nonconsumers, the multivariable-adjusted hazard ratio for all-cause mortality was 0.79 [95% confidence intervals (CI): 0.7, 0.89] for any berry consumption, 0.86 (0.75, 0.99) for strawberry consumption 0.79 (0.66, 0.95) for blueberries, and 0.69 (0.51, 0.93) for cranberries. Compared with the lower median of intake, risk of all-cause mortality for greater intake was 0.85 (0.74, 0.97) for total flavonoids, 0.85 (0.76, 0.95) for anthocyanidins, 0.9 (0.82, 0.99) for flavan-3-ols, 0.89 (0.79, 0.9) for flavanols, and 0.89 (0.8, 0.99) for flavones. There was a dose-response relationship between intakes of total flavonoids, anthocyanidins, and flavones and lower all-cause mortality risks (Ptrend < 0.05). Risk for cardiometabolic mortality was 0.75 (0.58, 0.98) for berry consumers and 0.49 (0.25, 0.98) for cranberry consumers. For respiratory disease mortality, risk was 0.41 (0.2, 0.86), compared with blueberry nonconsumers. CONCLUSION Higher intakes of berries and flavonoids were associated with a lower overall mortality risk in adult Americans. Few adults regularly consume berries, indicating that increased intake of berries and flavonoid-rich foods may be beneficial to health.
Collapse
Affiliation(s)
- Li Zhang
- Department of Public Health Sciences, Penn State College of Medicine, Penn State Cancer Institute, Pennsylvania State University, Hershey, PA, United States.
| | - Joshua E Muscat
- Department of Public Health Sciences, Penn State College of Medicine, Penn State Cancer Institute, Pennsylvania State University, Hershey, PA, United States
| | - Vernon M Chinchilli
- Department of Public Health Sciences, Penn State College of Medicine, Penn State Cancer Institute, Pennsylvania State University, Hershey, PA, United States
| | - Penny M Kris-Etherton
- Department of Nutritional Sciences, Pennsylvania State University, University Park, PA, United States
| | - Laila Al-Shaar
- Department of Public Health Sciences, Penn State College of Medicine, Penn State Cancer Institute, Pennsylvania State University, Hershey, PA, United States
| | - John P Richie
- Department of Public Health Sciences, Penn State College of Medicine, Penn State Cancer Institute, Pennsylvania State University, Hershey, PA, United States
| |
Collapse
|
7
|
Fabjanowicz M, Różańska A, Abdelwahab NS, Pereira-Coelho M, Haas ICDS, Madureira LADS, Płotka-Wasylka J. An analytical approach to determine the health benefits and health risks of consuming berry juices. Food Chem 2024; 432:137219. [PMID: 37647705 DOI: 10.1016/j.foodchem.2023.137219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2023] [Revised: 07/30/2023] [Accepted: 08/17/2023] [Indexed: 09/01/2023]
Abstract
Food products composition analysis is a prerequisite for verification of product quality, fulfillment of regulatory enforcements, checking compliance with national and international food standards, contracting specifications, and nutrient labeling requirements and providing quality assurance for use of the product for the supplementation of other foods. These aspects also apply to the berry fruit and berry juice. It also must be noted that even though fruit juices are generally considered healthy, there are many risks associated with mishandling both fruits and juices themselves. The review gathers information related with the health benefits and risk associated with the consumption of berry fruit juices. Moreover, the focus was paid to the quality assurance of berry fruit juice. Thus, the analytical methods used for determination of compounds influencing the sensory and nutritional characteristics of fruit juice as well as potential contaminants or adulterations.
Collapse
Affiliation(s)
- Magdalena Fabjanowicz
- Department of Analytical Chemistry, Faculty of Chemistry, Gdańsk University of Technology, 11/12 Narutowicza Street, 80-233 Gdańsk, Poland.
| | - Anna Różańska
- Department of Analytical Chemistry, Faculty of Chemistry, Gdańsk University of Technology, 11/12 Narutowicza Street, 80-233 Gdańsk, Poland
| | - Nada S Abdelwahab
- Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt
| | - Marina Pereira-Coelho
- Departament of Chemistry, Federal University of Santa Catarina, Des. Vitor Lima Av., Trindade, 88040-900 Florianópolis, SC, Brazil
| | - Isabel Cristina da Silva Haas
- Department of Food Science and Technology, Federal University of Santa Catarina, Admar Gonzaga Rd., 1346, Itacorubi, 88034-001 Florianópolis, SC, Brazil
| | | | - Justyna Płotka-Wasylka
- Department of Analytical Chemistry, Faculty of Chemistry, Gdańsk University of Technology, 11/12 Narutowicza Street, 80-233 Gdańsk, Poland; BioTechMed Center, Gdańsk University of Technology, 11/12 Narutowicza Street, 80-233 Gdańsk, Poland.
| |
Collapse
|
8
|
Dinesh S, Sharma S, Chourasiya R. Therapeutic Applications of Plant and Nutraceutical-Based Compounds for the Management of Type 2 Diabetes Mellitus: A Narrative Review. Curr Diabetes Rev 2024; 20:e050523216593. [PMID: 37151065 DOI: 10.2174/1573399819666230505140206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/07/2022] [Revised: 03/15/2023] [Accepted: 03/15/2023] [Indexed: 05/09/2023]
Abstract
Diabetes mellitus is a condition caused by a deficiency in insulin production or sensitivity that is defined by persistent hyperglycemia as well as disturbances in glucose, lipid, and protein metabolism. Uncurbed diabetes or incessant hyperglycemic condition can lead to severe complications, including renal damage, visual impairment, cardiovascular disease, neuropathy, etc., which promotes diabetes-associated morbidity and mortality rates. The therapeutic management of diabetes includes conventional medications and nutraceuticals as complementary therapies. Nutraceuticals are bioactive compounds derived from food sources that have health-promoting properties and are instrumental in the management and treatment of various maladies. Nutraceuticals are clinically exploited to tackle DM pathogenesis, and the clinical evidence suggests that nutraceuticals can modulate biochemical parameters related to diabetes pathogenesis and comorbidities. Hypoglycemic medicines are designed to mitigate DM in traditional medicinal practice. This review intends to emphasize and comment on the various therapeutic strategies available to manage this chronic condition, conventional drugs, and the potential role of nutraceuticals in managing the complexity of the disease and reducing the risk of complications. In contrast to conventional antihyperglycemic drugs, nutraceutical supplements offer a higher efficacy and lesser adverse effects. To substantiate the efficacy and safety of various functional foods in conjunction with conventional hypoglycemic medicines, additional data from clinical studies are required.
Collapse
Affiliation(s)
- Susha Dinesh
- Department of Bioinformatics, BioNome, Bengaluru, 560043, India
| | - Sameer Sharma
- Department of Bioinformatics, BioNome, Bengaluru, 560043, India
| | | |
Collapse
|
9
|
Chen J, Jin L, Chen M, Xu K, Huang Q, He B. Application of natural compounds in the treatment and prevention of prediabetes. Front Nutr 2023; 10:1301129. [PMID: 38099180 PMCID: PMC10719952 DOI: 10.3389/fnut.2023.1301129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2023] [Accepted: 11/13/2023] [Indexed: 12/17/2023] Open
Abstract
Prediabetes is an intermediate stage in the development of type 2 diabetes mellitus characterized by impaired fasting glucose and/or impaired glucose tolerance. Prediabetes generally has no obvious clinical symptoms, and most patients are found in health examinations or due to other diseases. Reactive hypoglycemia may indicate the possibility of early diabetes. Without effective preventive measures, prediabetes can progress to diabetes leading to serious public health problems. Therefore, early diagnosis and intervention are important. Many animal experiments and clinical trials have proven that natural compounds substantially improve glucose metabolism disorder. The active ingredients are mainly alkaloids, polysaccharides, saponins, terpenoids, flavonoids and polyphenols. Their mechanism of action mainly involves improved insulin sensitivity and insulin resistance, inhibited activity of alpha-glucosidase, antioxidant activity, anti-inflammatory, regulation of gut microbiota and activating of peroxisome proliferator-activated receptor-γ. This paper reviews the mechanisms of action of natural compounds on prediabetes and the status of related research.
Collapse
Affiliation(s)
- Jie Chen
- The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China
| | - Li Jin
- School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China
| | - Mengyao Chen
- The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China
| | - Kai Xu
- The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China
| | - Qi Huang
- The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China
| | - Beihui He
- The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China
| |
Collapse
|
10
|
Impellizzeri D, Siracusa R, D'Amico R, Fusco R, Cordaro M, Cuzzocrea S, Di Paola R. Açaí berry ameliorates cognitive impairment by inhibiting NLRP3/ASC/CASP axis in STZ-induced diabetic neuropathy in mice. J Neurophysiol 2023; 130:671-683. [PMID: 37584088 DOI: 10.1152/jn.00239.2023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2023] [Revised: 08/07/2023] [Accepted: 08/07/2023] [Indexed: 08/17/2023] Open
Abstract
Diabetes complications such as diabetic peripheral neuropathy (DPN) are linked to morbidity and mortality. Peripheral nerve damages in DPN are accompanied by discomfort, weakness, and sensory loss. Some drugs may demonstrate their therapeutic promise by reducing neuroinflammation, but they have side effects. Based on these considerations, the objective of this study was to examine the beneficial properties of açaí berry in a mouse model of DPN generated by injection of streptozotocin (STZ). Açaí berry was given orally to diabetic and control mice every day beginning 2 wk after STZ injection. The animals were euthanized after 16 wk, and tissues from the spinal cord and sciatic nerve and urine were taken. Our findings showed that daily treatment of açaí berry at a dose of 500 mg/kg was able to prevent behavioral changes as well as mast cell activation and nerve deterioration via NOD-like receptor family pyrin-domain-containing-3 (NLRP3)/apoptosis-associated speck-like protein containing a card (ASC)/caspase (CASP) regulation after diabetes induction.NEW & NOTEWORTHY Our research shows that açaí berry reduces mast cells degranulation and histological damage in diabetic neuropathy, improves physiological defense against reactive oxygen species, modulates the NLRP3/ASC/CASP axis, and ameliorates inflammation and oxidative stress. Diet could help treatment for diabetic peripheral neuropathy.
Collapse
Affiliation(s)
- Daniela Impellizzeri
- Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Italy
| | - Rosalba Siracusa
- Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Italy
| | - Ramona D'Amico
- Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Italy
| | - Roberta Fusco
- Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Italy
| | - Marika Cordaro
- Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy
| | - Salvatore Cuzzocrea
- Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Italy
| | - Rosanna Di Paola
- Department of Veterinary Sciences, University of Messina, Messina, Italy
| |
Collapse
|
11
|
Pires C. Superfoods for Type 2 Diabetes: A Narrative Review and Proposal for New International Recommendations. MEDICINA (KAUNAS, LITHUANIA) 2023; 59:1184. [PMID: 37511996 PMCID: PMC10384771 DOI: 10.3390/medicina59071184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/12/2023] [Revised: 05/31/2023] [Accepted: 06/19/2023] [Indexed: 07/30/2023]
Abstract
Background and Objectives: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease affecting an estimated 537 million individuals worldwide. 'Superfoods' can be integrated into the diet of T2DM patients due to their health benefits. Study Objectives: (i) To carry out a narrative review of 'superfoods' with the potential to reduce glycaemic levels in T2DM patients (2019 to 2022), (ii) to identify 'superfoods' with the potential to reduce HbA1c and (iii) to propose new guidance on the use of 'superfoods'. Materials and Methods: A narrative review was carried out using the databases PubMed, SciELO, DOAJ and Google Scholar. The keywords were ["type 2 diabetes" and ("food" or "diet" or "nutrition") and ("glycaemia" or "glycemia")]. Only review studies were included. Results: Thirty reviews were selected. The 'superfoods' identified as having a potential impact on glycaemic control were foods with polyphenols (e.g., berries), fermented dairy products, whole cereals/grains, nuts and proteins, among others. The possibility of an extensive reduction in Hb1Ac was reported for fermented dairy products, especially yoghurts enriched with vitamin D or probiotics (HbA1c reduction of around 1%) or by increasing the fibre intake by 15 g (or up to 35 g) (HbA1c reduction of around 2%). Conclusion: It is recommended that the identified 'superfoods' are included in the diet of T2DM patients, although this should not substitute an appropriate diet and exercise plan. In particular, yoghurts and an increased fibre intake (by 15 g or up to 35 g) can be used as nutraceuticals. New recommendations on the introduction of 'superfoods' in the diet of T2DM patients have been proposed.
Collapse
Affiliation(s)
- Carla Pires
- CBIOS-Research Center for Biosciences & Health Technologies, Universidade Lusófona, Campo Grande 376, 1749-024 Lisbon, Portugal
| |
Collapse
|
12
|
Lovell ST, Krishnaswamy K, Lin CH, Meier N, Revord RS, Thomas AL. Nuts and berries from agroforestry systems in temperate regions can form the foundation for a healthier human diet and improved outcomes from diet-related diseases. AGROFORESTRY SYSTEMS 2023:1-14. [PMID: 37363637 PMCID: PMC10249563 DOI: 10.1007/s10457-023-00858-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 09/06/2022] [Accepted: 05/15/2023] [Indexed: 06/28/2023]
Abstract
Agroforestry is a specific type of agroecosystem that includes trees and shrubs with the potential to yield nutrient-rich products that contribute to human health. This paper reviews the literature on the human health benefits of tree nut and berry species commonly associated with agroforestry systems of the United States, considering their potential for preventing certain diet-related diseases. Emphasis is placed on those diseases that are most closely associated with poor outcomes from COVID-19, as they are indicators of confounding health prognoses. Results indicate that tree nuts reduce the risk of coronary heart disease, and walnuts (Juglans species) are particularly effective because of their unique fatty acid profile. Berries that are grown on shrubs have the potential to contribute to mitigation of hypertension, prevention of Type II diabetes, and reduced risk of cardiovascular disease. To optimize human health benefits, plant breeding programs can focus on the traits that enhance the naturally-occurring phytochemicals, through biofortification. Value-added processing techniques should be selected and employed to preserve the phytonutrients, so they are maintained through the point of consumption. Agroforestry systems can offer valuable human health outcomes for common diet-related diseases, in addition to providing many environmental benefits, particularly if they are purposefully designed with that goal in mind. The food system policies in the U.S. might be reoriented to prioritize these food production systems based on the health benefits.
Collapse
Affiliation(s)
- Sarah Taylor Lovell
- Center for Agroforestry, University of Missouri, Columbia, MO USA
- School of Natural Resources, University of Missouri, Columbia, MO USA
| | - Kiruba Krishnaswamy
- Biomedical, Biological and Chemical Engineering, University of Missouri, Columbia, MO USA
| | - Chung-Ho Lin
- Center for Agroforestry, University of Missouri, Columbia, MO USA
- School of Natural Resources, University of Missouri, Columbia, MO USA
| | - Nicholas Meier
- Center for Agroforestry, University of Missouri, Columbia, MO USA
- School of Natural Resources, University of Missouri, Columbia, MO USA
| | - Ronald S. Revord
- Center for Agroforestry, University of Missouri, Columbia, MO USA
- School of Natural Resources, University of Missouri, Columbia, MO USA
| | - Andrew L. Thomas
- Division of Plant Sciences and Technology, Southwest Research, Extension, and Education Center, University of Missouri, Mt. Vernon, MO USA
| |
Collapse
|
13
|
Cui K, Li Z. Identification and analysis of type 2 diabetes-mellitus-associated autophagy-related genes. Front Endocrinol (Lausanne) 2023; 14:1164112. [PMID: 37223013 PMCID: PMC10200926 DOI: 10.3389/fendo.2023.1164112] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/12/2023] [Accepted: 04/06/2023] [Indexed: 05/25/2023] Open
Abstract
Introduction Autophagy, an innate safeguard mechanism for protecting the organism against harmful agents, is implicated in the survival of pancreatic â cells and the development of type 2 diabetes mellitus (T2DM). Potential autophagy-related genes (ARGs) may serve as potential biomarkers for T2DM treatment. Methods The GSE25724 dataset was downloaded from the Gene Expression Omnibus (GEO) database, and ARGs were obtained from the Human Autophagy Database. The differentially expressed autophagy-related genes (DEARGs) were screened at the intersection of ARGs and differentially expressed genes (DEGs) between T2DM and non-diabetic islet samples, which were subjected to functional enrichment analyses. A protein-protein interaction (PPI) network was constructed to identify hub DEARGs. Expressions of top 10 DEARGs were validated in human pancreatic â-cell line NES2Y and rat pancreatic INS-1 cells using quantitative reverse transcription polymerase chain reaction (qRT-PCR). Cell viability and insulin secretion were measured after cell transfection with lentiviral vector EIF2AK3 or RB1CC1 into islet cells. Results In total, we discovered 1,270 DEGs (266 upregulated and 1,004 downregulated genes) and 30 DEARGs enriched in autophagy- and mitophagy-related pathways. In addition, we identified GAPDH, ITPR1, EIF2AK3, FOXO3, HSPA5, RB1CC1, LAMP2, GABARAPL2, RAB7A, and WIPI1 genes as the hub ARGs. Next, qRT-PCR analysis revealed that expressions of hub DEARGs were consistent with findings from bioinformatics analysis. EIF2AK3, GABARAPL2, HSPA5, LAMP2, and RB1CC1 were both differentially expressed in the two cell types. Overexpression of EIF2AK3 or RB1CC1 promoted cell viability of islet cells and increased the insulin secretion. Discussion This study provides potential biomarkers as therapeutic targets for T2DM.
Collapse
Affiliation(s)
- Kun Cui
- Respiratory Medicine, Tangshan Gongren Hospital, Tangshan, Hebei, China
| | - Zhizheng Li
- Department of Respiratory and Critical Care Medicine, Tangshan Gongren Hospital, Tangshan, Hebei, China
| |
Collapse
|
14
|
Jin L, Dang H, Wu J, Yuan L, Chen X, Yao J. Supplementation of Weizmannia coagulans BC2000 and Ellagic Acid Inhibits High-Fat-Induced Hypercholesterolemia by Promoting Liver Primary Bile Acid Biosynthesis and Intestinal Cholesterol Excretion in Mice. Microorganisms 2023; 11:microorganisms11020264. [PMID: 36838229 PMCID: PMC9964488 DOI: 10.3390/microorganisms11020264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2023] [Revised: 01/13/2023] [Accepted: 01/17/2023] [Indexed: 01/20/2023] Open
Abstract
The probiotic Weizmannia coagulans (W. coagulans) BC2000 can increase the abundance of intestinal transforming ellagic acid (EA) bacteria and inhibit metabolic disorders caused by hyperlipidemia by activating liver autophagy. This study aimed to investigate the inhibitory effects of W. coagulans BC2000 and EA on hyperlipidemia-induced cholesterol metabolism disorders. C57BL/6J mice (n = 10 in each group) were fed a low-fat diet, high-fat diet (HFD), HFD supplemented with EA, HFD supplemented with EA and W. coagulans BC77, HFD supplemented with EA, and W. coagulans BC2000. EA and W. coagulans BC2000 supplementation prevented HFD-induced hypercholesterolemia and promoted fecal cholesterol excretion. Transcriptome analysis showed that primary bile acid biosynthesis in the liver was significantly activated by EA and W. coagulans BC2000 treatments. EA and W. coagulans BC2000 treatment also significantly increased the intestinal Eggerthellaceae abundance and the liver EA metabolites, iso-urolithin A, Urolithin A, and Urolithin B. Therefore, W. coagulans BC2000 supplementation promoted the intestinal transformation of EA, which led to the upregulation of liver bile synthesis, thus preventing hypercholesterolemia.
Collapse
Affiliation(s)
- Long Jin
- Institute of Plasma Physics, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei 230031, China
- Science Island Branch, Graduate School of University of Science and Technology of China, Hefei 230026, China
- Probiotics Institute, Hefei 230031, China
| | - Hongyang Dang
- College Life Science & Technology, Xinjiang University, Urumqi 830046, China
- Institute of Nutrition and Health, Qingdao University, Qingdao 266021, China
| | - Jinyong Wu
- Institute of Plasma Physics, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei 230031, China
| | - Lixia Yuan
- Institute of Plasma Physics, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei 230031, China
| | - Xiangsong Chen
- Institute of Plasma Physics, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei 230031, China
- Correspondence: (X.C.); (J.Y.)
| | - Jianming Yao
- Institute of Plasma Physics, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei 230031, China
- Science Island Branch, Graduate School of University of Science and Technology of China, Hefei 230026, China
- Correspondence: (X.C.); (J.Y.)
| |
Collapse
|
15
|
Ghalandari H, Askarpour M, Setayesh L, Ghaedi E. Effect of plum supplementation on blood pressure, weight indices, and C-reactive protein: A systematic review and meta-analysis of randomized controlled trials. Clin Nutr ESPEN 2022; 52:285-295. [PMID: 36513468 DOI: 10.1016/j.clnesp.2022.09.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2022] [Revised: 08/13/2022] [Accepted: 09/07/2022] [Indexed: 01/28/2023]
Abstract
INTRODUCTION Metabolic syndrome and its components are major health concerns around the world. Among various factors, overweight/obesity, its consequent inflammation, and hypertension are of special importance. Plums are anti-oxidant-rich fruits which have long been investigated for their health benefits. In this systematic review and meta-analysis, we investigated the possible impact of plum supplementation on obesity, inflammation, and blood pressure. METHODS All of the major databases (PubMed, Scopus, Cochrane, and Web of Science, Google Scholar and EMBASE) were searched to obtain the articles eligible for the review. Relevant data was extracted for the final analysis. Weighted mean difference (WMD) was obtained using fixed and random effect models. The main outcomes included systolic and diastolic blood pressure, body weight, body mass index (BMI), body fat percentage, waist circumference (WC) and blood C-reactive protein (CRP) levels. The effect sizes were expressed as weighted mean difference (WMD) and 95% confidence intervals (CI). RESULTS Crude search provided 3121 articles, among which 11 were eligible to be included. After crude and subgroup analysis, we were unable to detect any significant impact of plum supplementation on body weight (weight mean difference (WMD) of 0.04 kg; 95% CI: -1.55, 1.63, p = 0.959), BMI (WMD 0.39 kg/m2; 95% CI: -0.11, 0.90, p = 0.125), body fat percentage (WMD = 0.59%; 95% CI: -0.41, 1.59, p = 0.249), waist circumference (WMD = 0.60 cm; 95% CI: -1.83, 3.04, p = 0.627), systolic blood pressure (WMD -1.24 mmHg; 95% CI: -3.08, 0.59, p = 0.185), diastolic blood pressure (WMD -4.32 mmHg (95% CI: -9.29, 0.65, p = 0.089), or inflammation indicated by C-reactive protein (CRP) levels (WMD = 0.23 mg/l; 95% CI: -0.27, 0.73, p = 0.371). CONCLUSION Our results show that plum supplementation has no positive effect on factors of metabolic syndrome. We recommend that further research in the form of clinical trials be conducted to make a clear conclusion as of the effectiveness of plum supplementation on parameters of metabolic syndrome.
Collapse
Affiliation(s)
- Hamid Ghalandari
- Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Moein Askarpour
- Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Leila Setayesh
- Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran
| | - Ehsan Ghaedi
- Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.
| |
Collapse
|
16
|
Antioxidant Action of Hesperis matronalis L. in Chronic Experimental Diabetes. Pharm Chem J 2022. [DOI: 10.1007/s11094-022-02759-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
17
|
Hameed A, Adamska-Patruno E, Godzien J, Czajkowski P, Miksza U, Pietrowska K, Fiedorczuk J, Moroz M, Bauer W, Sieminska J, Górska M, Krętowski AJ, Ciborowski M. The Beneficial Effect of Cinnamon and Red Capsicum Intake on Postprandial Changes in Plasma Metabolites Evoked by a High-Carbohydrate Meal in Men with Overweight/Obesity. Nutrients 2022; 14:nu14204305. [PMID: 36296989 PMCID: PMC9610620 DOI: 10.3390/nu14204305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2022] [Revised: 10/05/2022] [Accepted: 10/10/2022] [Indexed: 01/24/2023] Open
Abstract
The relationship of high-carbohydrate (HC) meal intake to metabolic syndrome is still not fully explained. Metabolomics has the potential to indicate metabolic pathways altered by HC meals, which may improve our knowledge regarding the mechanisms by which HC meals may contribute to metabolic syndrome development. The fasting and postprandial metabolic response to HC or normo-carbohydrate (NC) meals with/without cinnamon + capsicum intake was evaluated using untargeted metabolomics and compared between normal-weight (NW) and overweight/obese (OW/OB) healthy men. Healthy male participants (age-matched) were divided into two groups (12 subjects per group). One was composed of men with normal weight (NW) and the other of men with overweight/obesity (OW/OB). On separate visits (with 2-3 week intervals), the participants received standardized HC or NC meals (89% or 45% carbohydrates, respectively). Fasting (0 min) and postprandial (30, 60, 120, 180 min) blood were collected for untargeted plasma metabolomics. Based on each metabolic feature's intensity change in time, the area under the curve (AUC) was calculated. Obtained AUCs were analyzed using multivariate statistics. Several metabolic pathways were found dysregulated after an HC meal in people from the OW/OB group but not the NW group. The consumption of HC meals by people with overweight/obesity led to a substantial increase in AUC, mainly for metabolites belonging to phospholipids and fatty acid amides. The opposite was observed for selected sphingolipids. The intake of cinnamon and capsicum normalized the concentration of selected altered metabolites induced by the intake of HC meals. A HC meal may induce an unfavourable postprandial metabolic response in individuals with overweight/obesity, and such persons should avoid HC meals.
Collapse
Affiliation(s)
- Ahsan Hameed
- Metabolomics Laboratory, Clinical Research Centre, Medical University of Bialystok, M. Sklodowskiej-Curie 24a, 15-276 Bialystok, Poland
| | - Edyta Adamska-Patruno
- Department of Nutriomics, Clinical Research Centre, Medical University of Bialystok, M. Sklodowskiej-Curie 24a, 15-276 Bialystok, Poland
- Clinical Support Research Centre, Medical University of Bialystok, M. Sklodowskiej-Curie 24a, 15-276 Bialystok, Poland
| | - Joanna Godzien
- Metabolomics Laboratory, Clinical Research Centre, Medical University of Bialystok, M. Sklodowskiej-Curie 24a, 15-276 Bialystok, Poland
| | - Przemyslaw Czajkowski
- Department of Nutriomics, Clinical Research Centre, Medical University of Bialystok, M. Sklodowskiej-Curie 24a, 15-276 Bialystok, Poland
- Clinical Support Research Centre, Medical University of Bialystok, M. Sklodowskiej-Curie 24a, 15-276 Bialystok, Poland
| | - Urszula Miksza
- Department of Nutriomics, Clinical Research Centre, Medical University of Bialystok, M. Sklodowskiej-Curie 24a, 15-276 Bialystok, Poland
- Clinical Support Research Centre, Medical University of Bialystok, M. Sklodowskiej-Curie 24a, 15-276 Bialystok, Poland
| | - Karolina Pietrowska
- Metabolomics Laboratory, Clinical Research Centre, Medical University of Bialystok, M. Sklodowskiej-Curie 24a, 15-276 Bialystok, Poland
| | - Joanna Fiedorczuk
- Department of Nutriomics, Clinical Research Centre, Medical University of Bialystok, M. Sklodowskiej-Curie 24a, 15-276 Bialystok, Poland
- Clinical Support Research Centre, Medical University of Bialystok, M. Sklodowskiej-Curie 24a, 15-276 Bialystok, Poland
| | - Monika Moroz
- Department of Nutriomics, Clinical Research Centre, Medical University of Bialystok, M. Sklodowskiej-Curie 24a, 15-276 Bialystok, Poland
- Clinical Support Research Centre, Medical University of Bialystok, M. Sklodowskiej-Curie 24a, 15-276 Bialystok, Poland
| | - Witold Bauer
- Clinical Research Centre, Medical University of Bialystok, M. Sklodowskiej-Curie 24a, 15-276 Bialystok, Poland
| | - Julia Sieminska
- Metabolomics Laboratory, Clinical Research Centre, Medical University of Bialystok, M. Sklodowskiej-Curie 24a, 15-276 Bialystok, Poland
| | - Maria Górska
- Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, ul. M. Sklodowskiej-Curie 24 A, 15-276 Bialystok, Poland
| | - Adam Jacek Krętowski
- Metabolomics Laboratory, Clinical Research Centre, Medical University of Bialystok, M. Sklodowskiej-Curie 24a, 15-276 Bialystok, Poland
- Department of Nutriomics, Clinical Research Centre, Medical University of Bialystok, M. Sklodowskiej-Curie 24a, 15-276 Bialystok, Poland
- Clinical Support Research Centre, Medical University of Bialystok, M. Sklodowskiej-Curie 24a, 15-276 Bialystok, Poland
- Clinical Research Centre, Medical University of Bialystok, M. Sklodowskiej-Curie 24a, 15-276 Bialystok, Poland
- Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, ul. M. Sklodowskiej-Curie 24 A, 15-276 Bialystok, Poland
| | - Michal Ciborowski
- Metabolomics Laboratory, Clinical Research Centre, Medical University of Bialystok, M. Sklodowskiej-Curie 24a, 15-276 Bialystok, Poland
- Correspondence:
| |
Collapse
|
18
|
Pomilio AB, Szewczuk NA, Duchowicz PR. Dietary anthocyanins balance immune signs in osteoarthritis and obesity - update of human in vitro studies and clinical trials. Crit Rev Food Sci Nutr 2022; 64:2634-2672. [PMID: 36148839 DOI: 10.1080/10408398.2022.2124948] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Anthocyanins are known to change ligand-receptor bindings, cell membrane permeability, and intracellular signaling pathways. The beneficial effects of dietary anthocyanins have been chronologically demonstrated in interventional and observational studies, including fourteen human chondrocyte studies and related cell culture assays, nineteen human clinical trials in osteoarthritis patients, seven in vivo obesity assays, nineteen in vitro assays in preadipocytes and related cells, and twenty-two clinical trials in overweight/obese subjects, which are critically discussed in this update. Strawberries, cherries, berries, pomegranate, tropical fruits, rosehip, purple rice, purple corn, red beans, and black soybean, together with cyanidin, delphinidin, malvidin, peonidin, some 3-O-glycosides, metabolites, and acylated anthocyanins from a potato cultivar have shown the best outcomes. The set of these five key tests and clinical trials, taken together, contributes to the understanding of the underlying mechanisms and pathways involved. Furthermore, this set shows the value of anthocyanins in counteracting the progression of osteoarthritis/obesity. The interplay between the inflammation of osteoarthritis and obesity, and the subsequent regulation/immunomodulation was performed through isolated and food anthocyanins. The antioxidant, anti-inflammatory, and immunomodulatory properties of anthocyanins explain the findings of the studies analyzed. However, further interventional studies should be conducted to finally establish the appropriate doses for anthocyanin supplementation, dose-response, and length of consumption, to include dietary recommendations for osteoarthritis/obese patients for preventive and management purposes.
Collapse
Affiliation(s)
- Alicia B Pomilio
- Laboratorio de Química y Bioquímica Estructural, CONICET, Área Hematología, Departamento de Bioquímica Clínica, Hospital de Clínicas "José de San Martín", Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Nicolas A Szewczuk
- Laboratorio de QSAR (Quantitative Structure-Activity Relationships), Instituto de Investigaciones Fisicoquímicas Teóricas y Aplicadas (INIFTA), CONICET, Departamento de Química, Universidad Nacional de La Plata (UNLP), Plata, Argentina
| | - Pablo R Duchowicz
- Laboratorio de QSAR (Quantitative Structure-Activity Relationships), Instituto de Investigaciones Fisicoquímicas Teóricas y Aplicadas (INIFTA), CONICET, Departamento de Química, Universidad Nacional de La Plata (UNLP), Plata, Argentina
| |
Collapse
|
19
|
Assunção-Júnior SO, Rodrigues LS, Raposo DS, Rodrigues JG, de Lima EJ, da Silva FM, Scudeller VV, Corrêa AL, Lima ES, Albuquerque PM, Koolen HH, Bataglion GA. Amazonian Melastomataceae blueberries: Determination of phenolic content, nutritional composition, and antioxidant and anti-glycation activities. Food Res Int 2022; 158:111519. [DOI: 10.1016/j.foodres.2022.111519] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2022] [Revised: 06/11/2022] [Accepted: 06/13/2022] [Indexed: 11/04/2022]
|
20
|
Huang F, Marungruang N, Kostiuchenko O, Kravchenko N, Burleigh S, Prykhodko O, Hållenius FF, Heyman-Lindén L. Identification of Nordic Berries with Beneficial Effects on Cognitive Outcomes and Gut Microbiota in High-Fat-Fed Middle-Aged C57BL/6J Mice. Nutrients 2022; 14:2734. [PMID: 35807915 PMCID: PMC9269296 DOI: 10.3390/nu14132734] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2022] [Revised: 06/25/2022] [Accepted: 06/27/2022] [Indexed: 02/07/2023] Open
Abstract
High-fat diets are associated with neuronal and memory dysfunction. Berries may be useful in improving age-related memory deficits in humans, as well as in mice receiving high-fat diets. Emerging research has also demonstrated that brain health and cognitive function may be related to the dynamic changes in the gut microbiota. In this study, the impact of Nordic berries on the brain and the gut microbiota was investigated in middle-aged C57BL/6J mice. The mice were fed high-fat diets (60%E fat) supplemented with freeze-dried powder (6% dwb) of bilberry, lingonberry, cloudberry, blueberry, blackcurrant, and sea buckthorn for 4 months. The results suggest that supplementation with bilberry, blackcurrant, blueberry, lingonberry, and (to some extent) cloudberry has beneficial effects on spatial cognition, as seen by the enhanced performance following the T-maze alternation test, as well as a greater proportion of DCX-expressing cells with prolongation in hippocampus. Furthermore, the proportion of the mucosa-associated symbiotic bacteria Akkermansia muciniphila increased by 4-14 times in the cecal microbiota of mice fed diets supplemented with lingonberry, bilberry, sea buckthorn, and blueberry. These findings demonstrate the potential of Nordic berries to preserve memory and cognitive function, and to induce alterations of the gut microbiota composition.
Collapse
Affiliation(s)
- Fang Huang
- Division of Biotechnology, Department of Chemistry, Lund University, 221 00 Lund, Sweden
- Aventure AB, Scheelevägen 22, 223 63 Lund, Sweden
| | | | - Olha Kostiuchenko
- Department of Food Technology, Engineering and Nutrition, Lund University, 221 00 Lund, Sweden; (O.K.); (N.K.); (S.B.); (O.P.); (F.F.H.)
- Department of Cytology, Bogomoletz Institute of Physiology, 010 24 Kyiv, Ukraine
| | - Nadiia Kravchenko
- Department of Food Technology, Engineering and Nutrition, Lund University, 221 00 Lund, Sweden; (O.K.); (N.K.); (S.B.); (O.P.); (F.F.H.)
- Department of Cytology, Bogomoletz Institute of Physiology, 010 24 Kyiv, Ukraine
| | - Stephen Burleigh
- Department of Food Technology, Engineering and Nutrition, Lund University, 221 00 Lund, Sweden; (O.K.); (N.K.); (S.B.); (O.P.); (F.F.H.)
| | - Olena Prykhodko
- Department of Food Technology, Engineering and Nutrition, Lund University, 221 00 Lund, Sweden; (O.K.); (N.K.); (S.B.); (O.P.); (F.F.H.)
| | - Frida Fåk Hållenius
- Department of Food Technology, Engineering and Nutrition, Lund University, 221 00 Lund, Sweden; (O.K.); (N.K.); (S.B.); (O.P.); (F.F.H.)
| | - Lovisa Heyman-Lindén
- Berry Lab AB, Scheelevägen 22, 223 63 Lund, Sweden; (N.M.); (L.H.-L.)
- Department of Experimental Medical Science, Lund University, 221 84 Lund, Sweden
| |
Collapse
|
21
|
Lin YY, Mattison MJ, Priefer R. Beneficial effects of non-herbal supplements on patients with diabetes. Diabetes Metab Syndr 2022; 16:102510. [PMID: 35613489 DOI: 10.1016/j.dsx.2022.102510] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/26/2022] [Revised: 05/11/2022] [Accepted: 05/13/2022] [Indexed: 11/30/2022]
Abstract
BACKGROUND AND AIMS Controlling glycemic levels is crucial for patients with diabetes mellitus to improve their disease management and health outcomes. Beyond lifestyle modification and pharmacotherapy, some supplements have been shown to lower blood glucose as well as mitigate diabetic complications. METHODS Information was primarily gathered by employing various PubMed scholarly articles for real-world examples in addition to data extraction from supplementary manuscripts. Only original human trials were used, and those published within the past two decades were primarily chosen. However, background information may contains review articles. RESULTS Some non-herbal supplements have been suggested to lower fasting blood glucose, postprandial glucose, glycated glucose (HbA1c), lipid profiles, oxidative stress, and inflammation, as well as improving body composition, insulin sensitivity, blood pressure, and nephropathy. CONCLUSION This review discusses ten non-herbal supplements that have been reported to have beneficial effects among different types of patients with diabetes as well as potential future clinical application. However, more long-term studies with a larger amount and more diverse participants need to be conducted for a robust conclusion. Also, mechanisms of action of antidiabetic effects are poorly understood and need further research.
Collapse
Affiliation(s)
- Yuan-Yuan Lin
- Massachusetts College of Pharmacy and Health Sciences University, Boston, MA, USA
| | | | - Ronny Priefer
- Massachusetts College of Pharmacy and Health Sciences University, Boston, MA, USA.
| |
Collapse
|
22
|
Functional Yogurt Fortified with Honey Produced by Feeding Bees Natural Plant Extracts for Controlling Human Blood Sugar Level. PLANTS 2022; 11:plants11111391. [PMID: 35684164 PMCID: PMC9182764 DOI: 10.3390/plants11111391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/22/2022] [Revised: 05/17/2022] [Accepted: 05/19/2022] [Indexed: 11/21/2022]
Abstract
The human blood sugar level is important and should be controlled to avoid any damage to nerves and blood vessels which could lead to heart disease and many other problems. Several market-available treatments for diabetes could be used, such as insulin therapy, synthetic drugs, herbal drugs, and transdermal patches, to help control blood sugar. In a double-blind human study, four kinds of honey from bees fed on acacia, sea buckthorn, chlorella alga, and green walnut extracts were used in fortifying yogurt for controlling human blood sugar. The impact of a previously fortified honey was investigated on blood levels and other parameters of healthy individuals in a human study with 60 participants. The participants received 150 mL of yogurt mixed with 30 g of honey every morning for 21 days. Before and after the study period, the basic blood parameters were tested, and the participants filled out standardized self-report questionnaires. Acacia honey was the traditional honey used as a control; the special honey products were produced by the patented technology. The consumption of green walnut honey had a significant effect on the morning blood sugar level, which decreased for every participant in the group (15 people). The average blood sugar level at the beginning in the walnut group was 4.81 mmol L−1, whereas the value after 21 days was 3.73 mmol L−1. The total decrease level of the individuals was about 22.45% (1.08 mmol L−1). Concerning the sea buckthorn and chlorella alga-based honey product groups, there was no significant change in the blood sugar level, which were recorded at 4.91 and 5.28 mmol L−1 before treatment and 5.28 and 5.07 mmol L−1 after, respectively. In the case of the acacia honey group, there was a slight significant decrease as well, it was 4.77 mmol L−1 at the beginning and 4.27 mmol L−1 at the end with a total decrease rate of 10.48%. It could thus be concluded that the active ingredients of green walnut can significantly decrease the blood sugar level in humans. This study, as a first report, is not only a new innovative process to add herbs or healthy active ingredients to honey but also shows how these beneficial ingredients aid the honey in controlling the human blood sugar level.
Collapse
|
23
|
Azzane A, Amssayef A, Eddouks M. Antihyperglycemic and antidyslipidemic Effect of Moricandia suffruticosa in Normal and Streptozotocin-Induced Diabetic Rats. Cardiovasc Hematol Disord Drug Targets 2022; 22:CHDDT-EPUB-123526. [PMID: 35570561 DOI: 10.2174/1871529x22666220513124452] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2022] [Revised: 02/28/2022] [Accepted: 03/12/2022] [Indexed: 11/22/2022]
Abstract
AIMS OF THE STUDY The present work aimed to assess the antihyperglycemic and antohyperlipidemic effects ofMoricandia suffruticosa. BACKGROUND Moricandia suffruticosa (M. suffruticosa) is used in traditional medicine. OBJECTIVE The present study investigated the antihyperglycemic and antidyslipidemic effects of M. suffruticosa and its effect on glycogen content in normoglycemic and hyperglycemic rats. METHODS The effect of the aqueous extract of M. suffruticosa (AEMS) at a two doses of 100 and 140 mg/kg on blood glucose levels, lipid, lipoprotein profile, and glycogen content was examined in normal and streptozotocin(STZ)-induced diabetic rats. On the other hand, a preliminary phytochemical screening and quantification of phenolic, flavonoid, and tannin contents were carried out. RESULTS The results demonstrated that AEMS exhibits antihyperglycemic activity in diabetic rats during both acute and subchronic essays. Furthermore, AEMS revealed an antidyslipidemic effect concerning the level of triglycerides, total cholesterol, very-low density lipoprotein (VLDL), and non-high density lipoproteins (Non-HDL). In contrast, AEMS has not affected the value of glycemia, lipids, and lipoproteins in normal rats. In addition, AEMS is rich in several phytochemical compounds. Furthermore, AEMS revealed an important in vitro antioxidant activity. CONCLUSION In conclusion, the study demonstrates that M. suffruticosa exhibits an important antihyperglycemic effect in diabetic rats.
Collapse
Affiliation(s)
- Amine Azzane
- Team of Ethnopharmacology & Pharmacognosy, Faculty of Sciences and Techniques Errachidia, Moulay Ismail University of Meknes, BP 509, Boutalamine, 52000. Errachidia. Morocco
| | - Ayoub Amssayef
- Team of Ethnopharmacology & Pharmacognosy, Faculty of Sciences and Techniques Errachidia, Moulay Ismail University of Meknes, BP 509, Boutalamine, 52000. Errachidia. Morocco
| | - Mohamed Eddouks
- Team of Ethnopharmacology & Pharmacognosy, Faculty of Sciences and Techniques Errachidia, Moulay Ismail University of Meknes, BP 509, Boutalamine, 52000. Errachidia. Morocco
| |
Collapse
|
24
|
Abioye RO, Okagu IU, Udenigwe CC. Targeting Glucose Transport Proteins for Diabetes Management: Regulatory Roles of Food-Derived Compounds. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY 2022; 70:5284-5290. [PMID: 35439410 DOI: 10.1021/acs.jafc.2c00817] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
With the rapid rise in prevalence, diabetes mellitus is one of the leading causes of mortality worldwide. Impaired cellular glucose transport is a major contributor to diabetes progression and, thus, an important target for treatment. Functional foods are a rich source of antidiabetic agents. These compounds target multiple physiological contributors to diabetes with lower risk for side effects. This perspective highlights recent advances in food-derived compounds that regulate the gene expression or activity of glucose transport proteins (SGLT1, SGLT2, GLUT1, GLUT2, and GLUT4) and provides insights for future research on targeting the transporters as a promising antidiabetic mechanism of nutraceutical compounds.
Collapse
Affiliation(s)
- Raliat O Abioye
- Department of Chemistry and Biomolecular Sciences, Faculty of Science, University of Ottawa, Ottawa, Ontario K1N 6N5, Canada
| | - Innocent U Okagu
- Department of Biochemistry, Faculty of Biological Sciences, University of Nigeria, Nsukka 410001, Nigeria
| | - Chibuike C Udenigwe
- Department of Chemistry and Biomolecular Sciences, Faculty of Science, University of Ottawa, Ottawa, Ontario K1N 6N5, Canada
- School of Nutrition Sciences, Faculty of Health Sciences, University of Ottawa, Ottawa, Ontario K1H 8M5, Canada
| |
Collapse
|
25
|
|
26
|
Olivera-Nappa Á, Contreras S, Tevy MF, Medina-Ortiz D, Leschot A, Vigil P, Conca C. Patient-Wise Methodology to Assess Glycemic Health Status: Applications to Quantify the Efficacy and Physiological Targets of Polyphenols on Glycemic Control. Front Nutr 2022; 9:831696. [PMID: 35252308 PMCID: PMC8892255 DOI: 10.3389/fnut.2022.831696] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2021] [Accepted: 01/25/2022] [Indexed: 11/13/2022] Open
Abstract
A growing body of evidence indicates that dietary polyphenols could be used as an early intervention to treat glucose-insulin (G-I) dysregulation. However, studies report heterogeneous information, and the targets of the intervention remain largely elusive. In this work, we provide a general methodology to quantify the effects of any given polyphenol-rich food or formulae over glycemic regulation in a patient-wise manner using an Oral Glucose Tolerance Test (OGTT). We use a mathematical model to represent individual OGTT curves as the coordinated action of subsystems, each one described by a parameter with physiological interpretation. Using the parameter values calculated for a cohort of 1198 individuals, we propose a statistical model to calculate the risk of dysglycemia and the coordination among subsystems for each subject, thus providing a continuous and individual health assessment. This method allows identifying individuals at high risk of dysglycemia—which would have been missed with traditional binary diagnostic methods—enabling early nutritional intervention with a polyphenol-supplemented diet where it is most effective and desirable. Besides, the proposed methodology assesses the effectiveness of interventions over time when applied to the OGTT curves of a treated individual. We illustrate the use of this method in a case study to assess the dose-dependent effects of Delphinol® on reducing dysglycemia risk and improving the coordination between subsystems. Finally, this strategy enables, on the one hand, the use of low-cost, non-invasive methods in population-scale nutritional studies. On the other hand, it will help practitioners assess the effectiveness of an intervention based on individual vulnerabilities and adapt the treatment to manage dysglycemia and avoid its progression into disease.
Collapse
Affiliation(s)
- Álvaro Olivera-Nappa
- Centre for Biotechnology and Bioengineering (CeBiB), University of Chile, Santiago, Chile
- Department of Chemical Engineering, Biotechnology and Materials, University of Chile, Santiago, Chile
- *Correspondence: Álvaro Olivera-Nappa
| | - Sebastian Contreras
- Max Planck Institute for Dynamics and Self-Organization, Göttingen, Germany
- Sebastian Contreras
| | - María Florencia Tevy
- Laboratory of Cell Biology, Institute of Nutrition and Food Technology (INTA), University of Chile, Santiago, Chile
| | - David Medina-Ortiz
- Centre for Biotechnology and Bioengineering (CeBiB), University of Chile, Santiago, Chile
- Department of Chemical Engineering, Biotechnology and Materials, University of Chile, Santiago, Chile
| | | | - Pilar Vigil
- Reproductive Health Research Institute, Santiago, Chile
| | - Carlos Conca
- Centre for Biotechnology and Bioengineering (CeBiB), University of Chile, Santiago, Chile
- Center for Mathematical Modelling (CMM), University of Chile, Santiago, Chile
| |
Collapse
|
27
|
Tresserra-Rimbau A, Castro-Barquero S, Becerra-Tomás N, Babio N, Martínez-González MÁ, Corella D, Fitó M, Romaguera D, Vioque J, Alonso-Gomez AM, Wärnberg J, Martínez JA, Serra-Majem L, Estruch R, Tinahones FJ, Lapetra J, Pintó X, Tur JA, López-Miranda J, Cano-Ibáñez N, Delgado-Rodríguez M, Matía-Martín P, Daimiel L, Martín Sánchez V, Vidal J, Vázquez C, Ros E, Basterra FJ, Fernández de la Puente M, Asensio EM, Castañer O, Bullón-Vela V, Tojal-Sierra L, Gómez-Gracia E, Cases-Pérez E, Konieczna J, García-Ríos A, Casañas-Quintana T, Bernal-Lopez MR, Santos-Lozano JM, Esteve-Luque V, Bouzas C, Vázquez-Ruiz Z, Palau-Galindo A, Barragan R, López Grau M, Razquín C, Goicolea-Güemez L, Toledo E, Vergaz MV, Lamuela-Raventós RM, Salas-Salvadó J. Adopting a High-Polyphenolic Diet Is Associated with an Improved Glucose Profile: Prospective Analysis within the PREDIMED-Plus Trial. Antioxidants (Basel) 2022; 11:antiox11020316. [PMID: 35204199 PMCID: PMC8868059 DOI: 10.3390/antiox11020316] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2022] [Revised: 01/30/2022] [Accepted: 02/01/2022] [Indexed: 02/05/2023] Open
Abstract
Previous studies suggested that dietary polyphenols could reduce the incidence and complications of type-2 diabetes (T2D); although the evidence is still limited and inconsistent. This work analyzes whether changing to a diet with a higher polyphenolic content is associated with an improved glucose profile. At baseline, and at 1 year of follow-up visits, 5921 participants (mean age 65.0 ± 4.9, 48.2% women) who had overweight/obesity and metabolic syndrome filled out a validated 143-item semi-quantitative food frequency questionnaire (FFQ), from which polyphenol intakes were calculated. Energy-adjusted total polyphenols and subclasses were categorized in tertiles of changes. Linear mixed-effect models with random intercepts (the recruitment centers) were used to assess associations between changes in polyphenol subclasses intake and 1-year plasma glucose or glycosylated hemoglobin (HbA1c) levels. Increments in total polyphenol intake and some classes were inversely associated with better glucose levels and HbA1c after one year of follow-up. These associations were modified when the analyses were run considering diabetes status separately. To our knowledge, this is the first study to assess the relationship between changes in the intake of all polyphenolic groups and T2D-related parameters in a senior population with T2D or at high-risk of developing T2D.
Collapse
Affiliation(s)
- Anna Tresserra-Rimbau
- Department of Nutrition, Food Science and Gastronomy, XIA, School of Pharmacy and Food Sciences, INSA, University of Barcelona, 08921 Barcelona, Spain;
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Correspondence:
| | - Sara Castro-Barquero
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Internal Medicine, Institut d’Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain
| | - Nerea Becerra-Tomás
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London W2 1PG, UK
- Unitat de Nutrició, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, 43204 Reus, Spain;
| | - Nancy Babio
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Unitat de Nutrició, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, 43204 Reus, Spain;
- Nutrition Unit, University Hospital of Sant Joan de Reus, 43204 Reus, Spain
- Institut d’Investigació Sanitària Pere Virgili (IISPV), 43204 Reus, Spain
| | - Miguel Ángel Martínez-González
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Preventive Medicine and Public Health, University of Navarra, IDISNA, 31008 Pamplona, Spain
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA
| | - Dolores Corella
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Preventive Medicine, University of Valencia, 46010 Valencia, Spain
| | - Montserrat Fitó
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Unit of Cardiovascular Risk and Nutrition, Institut Hospital del Mar de Investigaciones Médicas Municipal d’Investigació Médica (IMIM), 08007 Barcelona, Spain
| | - Dora Romaguera
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Research Group on Nutritional Epidemiology & Cardiovascular Physiopathology (NUTRECOR), Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain
| | - Jesús Vioque
- CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain; (J.V.); (N.C.-I.); (M.D.-R.); (V.M.S.)
- Alicante Institute for Health and Biomedical Research, University Miguel Hernandez (ISABIAL-UMH), 03010 Alicante, Spain
| | - Angel M. Alonso-Gomez
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Bioaraba Health Research Institute, Osakidetza Basque Health Service, Araba University Hospital, University of the Basque Country UPV/EHU, 01009 Vitoria-Gasteiz, Spain
| | - Julia Wärnberg
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Nursing, Institute of Biomedical Research in Málaga (IBIMA), University of Málaga, 29010 Malaga, Spain
| | - José Alfredo Martínez
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Nutrition, Food Sciences, and Physiology, Center for Nutrition Research, University of Navarra, 31008 Pamplona, Spain;
- Cardiometabolic Nutrition Group, IMDEA Food, CEI UAM + CSIC, 28049 Madrid, Spain
| | - Luís Serra-Majem
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Research Institute of Biomedical and Health Sciences (IUIBS), University of Las Palmas de Gran Canaria & Centro Hospitalario Universitario Insular Materno Infantil (CHUIMI), Canarian Health Service, 35016 Las Palmas de Gran Canaria, Spain
| | - Ramon Estruch
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Internal Medicine, Institut d’Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain
| | - Francisco J. Tinahones
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Internal Medicine, Regional University Hospital of Malaga, Instituto de Investigación Biomédica de Malaga (IBIMA), University of Malaga, 29010 Malaga, Spain
| | - José Lapetra
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Family Medicine, Research Unit, Distrito Sanitario Atención Primaria Sevilla, 41010 Sevilla, Spain
| | - Xavier Pintó
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Lipids and Vascular Risk Unit, Internal Medicine, Hospital Universitario de Bellvitge, 08908 Hospitalet de Llobregat, Spain;
| | - Josep A. Tur
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Research Group on Community Nutrition & Oxidative Stress, University of Balearic Islands-IUNICS, 07122 Palma de Mallorca, Spain
| | - José López-Miranda
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, 14004 Cordoba, Spain
| | - Naomi Cano-Ibáñez
- CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain; (J.V.); (N.C.-I.); (M.D.-R.); (V.M.S.)
- Department of Preventive Medicine and Public Health, University of Granada, 18016 Granada, Spain
- Instituto de Investigación Biosanitaria, Complejo Hospitales Universitarios de Granada, Universidad de Granada, 18016 Granada, Spain
| | - Miguel Delgado-Rodríguez
- CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain; (J.V.); (N.C.-I.); (M.D.-R.); (V.M.S.)
- Division of Preventive Medicine, Faculty of Medicine, University of Jaén, 23071 Jaen, Spain
| | - Pilar Matía-Martín
- Department of Endocrinology and Nutrition, Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain;
| | - Lidia Daimiel
- Nutritional Control of the Epigenome Group, Precision Nutrition and Obesity Program, IMDEA Food, CEI UAM + CSIC, 28029 Madrid, Spain;
| | - Vicente Martín Sánchez
- CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain; (J.V.); (N.C.-I.); (M.D.-R.); (V.M.S.)
- Institute of Biomedicine (IBIOMED), University of León, 24071 Leon, Spain
| | - Josep Vidal
- CIBER Diabetes y Enfermedades Metabólicas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain;
- Department of Endocrinology, Institut d’Investigacions Biomédiques August Pi Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain
| | - Clotilde Vázquez
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Endocrinology and Nutrition, Hospital Fundación Jimenez Díaz, Instituto de Investigaciones Biomédicas IISFJD, University Autonoma, 28040 Madrid, Spain
| | - Emili Ros
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Lipid Clinic, Department of Endocrinology and Nutrition, Institut d’Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clínic, 08036 Barcelona, Spain
| | - Francisco Javier Basterra
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Preventive Medicine and Public Health, University of Navarra, IDISNA, 31008 Pamplona, Spain
| | - María Fernández de la Puente
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Unitat de Nutrició, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, 43204 Reus, Spain;
- Nutrition Unit, University Hospital of Sant Joan de Reus, 43204 Reus, Spain
| | - Eva M. Asensio
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Preventive Medicine, University of Valencia, 46010 Valencia, Spain
| | - Olga Castañer
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Unit of Cardiovascular Risk and Nutrition, Institut Hospital del Mar de Investigaciones Médicas Municipal d’Investigació Médica (IMIM), 08007 Barcelona, Spain
| | - Vanessa Bullón-Vela
- Department of Nutrition, Food Sciences, and Physiology, Center for Nutrition Research, University of Navarra, 31008 Pamplona, Spain;
| | - Lucas Tojal-Sierra
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Bioaraba Health Research Institute, Osakidetza Basque Health Service, Araba University Hospital, University of the Basque Country UPV/EHU, 01009 Vitoria-Gasteiz, Spain
| | - Enrique Gómez-Gracia
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Preventive Medicine and Public Health, Instituto de Investigación Biomédica de Málaga-IBIMA, School of Medicine, University of Málaga, 29071 Malaga, Spain
| | | | - Jadwiga Konieczna
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Research Group on Nutritional Epidemiology & Cardiovascular Physiopathology (NUTRECOR), Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain
| | - Antonio García-Ríos
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, 14004 Cordoba, Spain
| | - Tamara Casañas-Quintana
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Research Institute of Biomedical and Health Sciences (IUIBS), University of Las Palmas de Gran Canaria & Centro Hospitalario Universitario Insular Materno Infantil (CHUIMI), Canarian Health Service, 35016 Las Palmas de Gran Canaria, Spain
| | - María Rosa Bernal-Lopez
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Internal Medicine, Regional University Hospital of Malaga, Instituto de Investigación Biomédica de Malaga (IBIMA), University of Malaga, 29010 Malaga, Spain
| | - José Manuel Santos-Lozano
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Family Medicine, Research Unit, Distrito Sanitario Atención Primaria Sevilla, 41010 Sevilla, Spain
| | - Virginia Esteve-Luque
- Lipids and Vascular Risk Unit, Internal Medicine, Hospital Universitario de Bellvitge, 08908 Hospitalet de Llobregat, Spain;
| | - Cristina Bouzas
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Research Group on Community Nutrition & Oxidative Stress, University of Balearic Islands-IUNICS, 07122 Palma de Mallorca, Spain
| | - Zenaida Vázquez-Ruiz
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Preventive Medicine and Public Health, University of Navarra, IDISNA, 31008 Pamplona, Spain
| | - Antoni Palau-Galindo
- Unitat de Nutrició, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, 43204 Reus, Spain;
- ABS Reus V. Centre d’Assistència Primària Marià Fortuny, SAGESSA, 43205 Reus, Spain
| | - Rocio Barragan
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Preventive Medicine, University of Valencia, 46010 Valencia, Spain
| | - Mercè López Grau
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Unit of Cardiovascular Risk and Nutrition, Institut Hospital del Mar de Investigaciones Médicas Municipal d’Investigació Médica (IMIM), 08007 Barcelona, Spain
| | - Cristina Razquín
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Nutrition, Food Sciences, and Physiology, Center for Nutrition Research, University of Navarra, 31008 Pamplona, Spain;
- Cardiometabolic Nutrition Group, IMDEA Food, CEI UAM + CSIC, 28049 Madrid, Spain
| | - Leire Goicolea-Güemez
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Bioaraba Health Research Institute, Osakidetza Basque Health Service, Araba University Hospital, University of the Basque Country UPV/EHU, 01009 Vitoria-Gasteiz, Spain
| | - Estefanía Toledo
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Preventive Medicine and Public Health, University of Navarra, IDISNA, 31008 Pamplona, Spain
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA
| | - Manel Vila Vergaz
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Unit of Cardiovascular Risk and Nutrition, Institut Hospital del Mar de Investigaciones Médicas Municipal d’Investigació Médica (IMIM), 08007 Barcelona, Spain
| | - Rosa M. Lamuela-Raventós
- Department of Nutrition, Food Science and Gastronomy, XIA, School of Pharmacy and Food Sciences, INSA, University of Barcelona, 08921 Barcelona, Spain;
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
| | - Jordi Salas-Salvadó
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Unitat de Nutrició, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, 43204 Reus, Spain;
- Nutrition Unit, University Hospital of Sant Joan de Reus, 43204 Reus, Spain
- Institut d’Investigació Sanitària Pere Virgili (IISPV), 43204 Reus, Spain
| |
Collapse
|
28
|
Li KP, Yuan M, Wu YL, Pineda M, Zhang CM, Chen YF, Chen ZQ, Rong XL, Turnbull JE, Guo J. A high-fat High-fructose Diet Dysregulates the Homeostatic Crosstalk Between Gut Microbiome, Metabolome and Immunity in an Experimental Model of Obesity. Mol Nutr Food Res 2022; 66:e2100950. [PMID: 35072983 DOI: 10.1002/mnfr.202100950] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2021] [Revised: 12/30/2021] [Indexed: 11/07/2022]
Abstract
SCOPE Ample evidence supports the prominent role of gut-liver axis in perpetuating pathological networks of high-fat high-fructose (HFF) diet induced metabolic disorders, however, the molecular mechanisms are still not fully understood. Herein, we aim to present a holistic delineation and scientific explanation for the crosstalk between the gut and liver, including the potential mediators involved in orchestrating the metabolic and immune systems. METHODS An experimental obesity associated metaflammation rat model was induced with a HFF diet. An integrative multi-omics analysis was then performed. Following the clues illustrated by the multi-omics discoveries, putative pathways were subsequently validated by RT-qPCR and Western blotting. RESULTS HFF diet led to obese phenotypes in rats, as well as histopathological changes. Integrated omics analysis showed there existed a strong interdependence among gut microbiota composition, intestinal metabolites and innate immunity regulation in the liver. Some carboxylic acids might contribute to gut-liver communication. Moreover, activation of the hepatic LPS-TLR4 pathway in obesity was confirmed. CONCLUSIONS HFF-intake disturbs gut flora homeostasis. Crosstalk between gut microbiota and innate immune system mediated hepatic metaflammation in obese rats, associated with LPS-TLR4 signaling pathway activation. Moreover, α-hydroxyisobutyric acid and some other organic acids may play a role as messengers in the liver-gut axis. High-fat high-fructose diet (HFF) induces obesity associated chronic inflammation; HFF dysregulates the rat intestinal metabolome and gut microbiota composition; HFF impacts hepatic expression of genes involved in innate immunity; Modulation of gut microbiota composition and innate immunity are connected partly via TLR4 signalling; Small molecular carboxylic acids are potential mediators of gut-liver axis communication in chronic obesity. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Kun-Ping Li
- Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Guangdong Pharmaceutical University, Guangzhou, 510006, China
- Key Laboratory of Glycolipid Metabolic Diseases, Ministry of Education, Guangzhou, 510006, China
| | - Min Yuan
- Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Guangdong Pharmaceutical University, Guangzhou, 510006, China
- Key Laboratory of Glycolipid Metabolic Diseases, Ministry of Education, Guangzhou, 510006, China
| | - Yong-Lin Wu
- Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Guangdong Pharmaceutical University, Guangzhou, 510006, China
- Key Laboratory of Glycolipid Metabolic Diseases, Ministry of Education, Guangzhou, 510006, China
| | - Miguel Pineda
- Institute of infection, immunity & inflammation, University of Glasgow, University Place, Glasgow, G12 8TA, UK
| | - Chu-Mei Zhang
- Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Guangdong Pharmaceutical University, Guangzhou, 510006, China
- Key Laboratory of Glycolipid Metabolic Diseases, Ministry of Education, Guangzhou, 510006, China
| | - Yan-Fen Chen
- School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, 510006, China
| | - Zhi-Quan Chen
- Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Guangdong Pharmaceutical University, Guangzhou, 510006, China
- Key Laboratory of Glycolipid Metabolic Diseases, Ministry of Education, Guangzhou, 510006, China
| | - Xiang-Lu Rong
- Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Guangdong Pharmaceutical University, Guangzhou, 510006, China
- Key Laboratory of Glycolipid Metabolic Diseases, Ministry of Education, Guangzhou, 510006, China
| | - Jeremy E Turnbull
- Department of Biochemistry and Systems Biology, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, L69 7ZB, UK
| | - Jiao Guo
- Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Guangdong Pharmaceutical University, Guangzhou, 510006, China
- Key Laboratory of Glycolipid Metabolic Diseases, Ministry of Education, Guangzhou, 510006, China
| |
Collapse
|
29
|
Zheng Q, Kebede MT, Lee B, Krasinski CA, Islam S, Wurfl LA, Kemeh MM, Ivancic VA, Jakobsche CE, Spratt DE, Lazo ND. Differential Effects of Polyphenols on Insulin Proteolysis by the Insulin-Degrading Enzyme. Antioxidants (Basel) 2021; 10:1342. [PMID: 34572974 PMCID: PMC8467823 DOI: 10.3390/antiox10091342] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2021] [Revised: 08/19/2021] [Accepted: 08/23/2021] [Indexed: 12/20/2022] Open
Abstract
The insulin-degrading enzyme (IDE) possesses a strong ability to degrade insulin and Aβ42 that has been linked to the neurodegeneration in Alzheimer's disease (AD). Given this, an attractive IDE-centric strategy for the development of therapeutics for AD is to boost IDE's activity for the clearance of Aβ42 without offsetting insulin proteostasis. Recently, we showed that resveratrol enhances IDE's activity toward Aβ42. In this work, we used a combination of chromatographic and spectroscopic techniques to investigate the effects of resveratrol on IDE's activity toward insulin. For comparison, we also studied epigallocatechin-3-gallate (EGCG). Our results show that the two polyphenols affect the IDE-dependent degradation of insulin in different ways: EGCG inhibits IDE while resveratrol has no effect. These findings suggest that polyphenols provide a path for developing therapeutic strategies that can selectively target IDE substrate specificity.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | - Noel D. Lazo
- Gustaf H. Carlson School of Chemistry and Biochemistry, Clark University, Worcester, MA 01610, USA; (Q.Z.); (M.T.K.); (B.L.); (C.A.K.); (S.I.); (L.A.W.); (M.M.K.); (V.A.I.); (C.E.J.); (D.E.S.)
| |
Collapse
|
30
|
Kim NY, Thomas SS, Hwang DI, Lee JH, Kim KA, Cha YS. Anti-Obesity Effects of Morus alba L. and Aronia melanocarpa in a High-Fat Diet-Induced Obese C57BL/6J Mouse Model. Foods 2021; 10:foods10081914. [PMID: 34441691 PMCID: PMC8391742 DOI: 10.3390/foods10081914] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2021] [Revised: 08/03/2021] [Accepted: 08/16/2021] [Indexed: 12/25/2022] Open
Abstract
The present study investigated the synergic effect of extracts of Morus alba (MA) and Aronia melanocarpa (Michx.) (AR) against high-fat diet induced obesity. Four-week-old male C57BL/6J mice were randomly divided into five groups that were fed for 14 weeks with a normal diet (ND), high-fat diet (HD), HD with M. alba 400 mg/kg body weight (MA), HD with A. melanocarpa 400 mg/kg body weight (AR), or HD with a mixture (1:1, v/v) of M. alba and A. melanocarpa (400 mg/kg) (MA + AR). Treatment with MA, AR, and MA + AR for 14 weeks reduced high fat diet-induced weight gain and improved serum lipid levels, and histological analysis revealed that MA and AR treatment markedly decreased lipid accumulation in the liver and adipocyte size in epididymal fat. Furthermore, micro-CT images showed MA + AR significantly reduced abdominal fat volume. Expression levels of genes involved in lipid anabolism, such as SREBP-1c, PPAR-γ, CEBPα, FAS, and CD36 were decreased by MA + AR treatment whereas PPAR-α, ACOX1, and CPT-1a levels were increased by MA + AR treatment. Protein expression of p-AMPK and p-ACC were increased in the MA + AR group, indicating that MA + AR ameliorated obesity by upregulating AMPK signaling. Together, our findings indicate that MA and AR exert a synergistic effect against diet-induced obesity and are promising agents for managing obesity.
Collapse
Affiliation(s)
- Na-Yeon Kim
- Department of Food Science and Human Nutrition & Obesity Research Center, Jeonbuk National University, Jeonju 54896, Korea;
| | - Shalom Sara Thomas
- Department of Nutrition, University of Massachusetts Amherst, Amherst, MA 02204, USA;
| | - Dae-Il Hwang
- Institute of Jinan Red Ginseng, Jinan-gun 55442, Korea; (D.-I.H.); (J.-H.L.)
| | - Ji-Hye Lee
- Institute of Jinan Red Ginseng, Jinan-gun 55442, Korea; (D.-I.H.); (J.-H.L.)
| | - Kyung-Ah Kim
- Department of Food and Nutrition, Chungnam National University, Daejeon 34134, Korea;
| | - Youn-Soo Cha
- Department of Food Science and Human Nutrition & Obesity Research Center, Jeonbuk National University, Jeonju 54896, Korea;
- Correspondence: ; Tel.: +82-63-270-3822
| |
Collapse
|
31
|
Hira T, Trakooncharoenvit A, Taguchi H, Hara H. Improvement of Glucose Tolerance by Food Factors Having Glucagon-Like Peptide-1 Releasing Activity. Int J Mol Sci 2021; 22:6623. [PMID: 34205659 PMCID: PMC8235588 DOI: 10.3390/ijms22126623] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2021] [Revised: 06/17/2021] [Accepted: 06/17/2021] [Indexed: 12/14/2022] Open
Abstract
Glucagon-like peptide-1 (GLP-1) is a gastrointestinal hormone released from enteroendocrine L cells in response to meal ingestion. GLP-1 receptor agonists and GLP-1 enhancers have been clinically employed to treat diabetes owing to their glucose-dependent insulin-releasing activity. The release of GLP-1 is primarily stimulated by macronutrients such as glucose and fatty acids, which are nutritionally indispensable; however, excessive intake of sugar and fat is responsible for the development of obesity and diabetes. Therefore, GLP-1 releasing food factors, such as dietary peptides and non-nutrients, are deemed desirable for improving glucose tolerance. Human and animal studies have revealed that dietary proteins/peptides have a potent effect on stimulating GLP-1 secretion. Studies in enteroendocrine cell models have shown that dietary peptides, amino acids, and phytochemicals, such as quercetin, can directly stimulate GLP-1 secretion. In our animal experiments, these food factors improved glucose metabolism and increased GLP-1 secretion. Furthermore, some dietary peptides not only stimulated GLP-1 secretion but also reduced plasma peptidase activity, which is responsible for GLP-1 inactivation. Herein, we review the relationship between GLP-1 and food factors, especially dietary peptides and flavonoids. Accordingly, utilization of food factors with GLP-1-releasing/enhancing activity is a promising strategy for preventing and treating obesity and diabetes.
Collapse
Affiliation(s)
- Tohru Hira
- Research Faculty of Agriculture, Hokkaido University, Sapporo 060-8589, Japan
- Graduate School of Agriculture, Hokkaido University, Sapporo 060-8589, Japan;
- School of Agriculture, Hokkaido University, Sapporo 060-8589, Japan;
| | | | - Hayate Taguchi
- School of Agriculture, Hokkaido University, Sapporo 060-8589, Japan;
| | - Hiroshi Hara
- Department of Food Science and Human Nutrition, Fuji Women’s University, Ishikari-shi 061-320, Japan;
| |
Collapse
|
32
|
Ren Z, Gong H, Zhao A, Zhang J, Yang C, Wang P, Zhang Y. Effect of Sea Buckthorn on Plasma Glucose in Individuals with Impaired Glucose Regulation: A Two-Stage Randomized Crossover Intervention Study. Foods 2021; 10:foods10040804. [PMID: 33917994 PMCID: PMC8068387 DOI: 10.3390/foods10040804] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2021] [Revised: 03/29/2021] [Accepted: 04/06/2021] [Indexed: 01/21/2023] Open
Abstract
Sea buckthorn (SB) has been indicated to have hypoglycemic potential, but its effects on glucose in people with impaired glucose regulation (IGR) are still unclear. This work presents a randomized, double-blinded, two-way crossover study. A total of 38 subjects with IGR completed the intervention of consuming sea buckthorn fruit puree (SBFP, 90 mL/day, five weeks), washing out (four weeks), and then consuming placebo (90 mL/day, five weeks) or in reverse order. In our methodology, a unified questionnaire was used to gather information on physical activity and dietary intakes, and physical examinations were performed to measure blood pressure, height, and weight. Fasting blood samples were collected to detect the fasting plasma glucose (FPG) and glycated serum protein (GSP). To calculate the area under the curve of 2 h postprandial plasma glucose (2 h PG-AUC), blood samples at t = 30, 60, and 120 min were also collected and analyzed. Effects of the intervention were evaluated by paired-sample Wilcoxon test and mixed model analyses. Our results show that the FPG in subjects with IGR decreased by a median reduction of 0.14 mmol/L after five weeks' consumption of SBFP, but increased by a median of 0.07 mmol/L after placebo intervention, and the comparison of these two interventions was statistically significant (p = 0.045). During the wash-out period, a similar difference was observed as the FPG decreased in the group that received SBFP intervention first, but increased in another group (p = 0.043). Both SBFP and placebo significantly raised GSP during the intervention period, but lowered it in the wash-out period (p < 0.05), while no significant difference was found between the two interventions. The 2 h PG-AUC remained relatively stable throughout the study. Our results indicated that consumption of SBFP for five weeks showed a slight downward trend on FPG in subjects with IGR.
Collapse
Affiliation(s)
- Zhongxia Ren
- Department of Nutrition and Food Hygiene, School of Public Health, Peking University Health Science Center, Beijing 100191, China; (Z.R.); (H.G.); (J.Z.); (C.Y.)
| | - Huiting Gong
- Department of Nutrition and Food Hygiene, School of Public Health, Peking University Health Science Center, Beijing 100191, China; (Z.R.); (H.G.); (J.Z.); (C.Y.)
| | - Ai Zhao
- Vanke School of Public Health, Tsinghua University, Beijing 100091, China;
| | - Jian Zhang
- Department of Nutrition and Food Hygiene, School of Public Health, Peking University Health Science Center, Beijing 100191, China; (Z.R.); (H.G.); (J.Z.); (C.Y.)
| | - Chenlu Yang
- Department of Nutrition and Food Hygiene, School of Public Health, Peking University Health Science Center, Beijing 100191, China; (Z.R.); (H.G.); (J.Z.); (C.Y.)
| | - Peiyu Wang
- Department of Social Science and Health Education, School of Public Health, Peking University Health Science Center, Beijing 100191, China;
| | - Yumei Zhang
- Department of Nutrition and Food Hygiene, School of Public Health, Peking University Health Science Center, Beijing 100191, China; (Z.R.); (H.G.); (J.Z.); (C.Y.)
- Correspondence:
| |
Collapse
|
33
|
Sarkar D, Christopher A, Shetty K. Phenolic Bioactives From Plant-Based Foods for Glycemic Control. Front Endocrinol (Lausanne) 2021; 12:727503. [PMID: 35116002 PMCID: PMC8805174 DOI: 10.3389/fendo.2021.727503] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/18/2021] [Accepted: 12/21/2021] [Indexed: 12/19/2022] Open
Abstract
Plant-based foods containing phenolic bioactives have human health protective functions relevant for combating diet and lifestyle-influenced chronic diseases, including type 2 diabetes (T2D). The molecular structural features of dietary phenolic bioactives allow antioxidant functions relevant for countering chronic oxidative stress-induced metabolic breakdown commonly associated with T2D. In addition to antioxidant properties, phenolic bioactives of diverse plant foods have therapeutic functional activities such as improving insulin sensitivity, reducing hepatic glucose output, inhibiting activity of key carbohydrate digestive enzymes, and modulating absorption of glucose in the bloodstream, thereby subsequently improving post-prandial glycemic control. These therapeutic functional properties have direct implications and benefits in the dietary management of T2D. Therefore, plant-based foods that are rich in phenolic bioactives are excellent dietary sources of therapeutic targets to improve overall glycemic control by managing chronic hyperglycemia and chronic oxidative stress, which are major contributing factors to T2D pathogenesis. However, in studies with diverse array of plant-based foods, concentration and composition of phenolic bioactives and their glycemic control relevant bioactivity can vary widely between different plant species, plant parts, and among different varieties/genotypes due to the different environmental and growing conditions, post-harvest storage, and food processing steps. This has allowed advances in innovative strategies to screen and optimize whole and processed plant derived foods and their ingredients based on their phenolic bioactive linked antioxidant and anti-hyperglycemic properties for their effective integration into T2D focused dietary solutions. In this review, different pre-harvest and post-harvest strategies and factors that influence phenolic bioactive-linked antioxidant and anti-hyperglycemic properties in diverse plant derived foods and derivation of extracts with therapeutic potential are highlighted and discussed. Additionally, novel bioprocessing strategies to enhance bioavailability and bioactivity of phenolics in plant-derived foods targeting optimum glycemic control and associated T2D therapeutic benefits are also advanced.
Collapse
|